MRVI INVESTOR NOTICE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and inadequate internal controls over financial reporting [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Nelson v. Maravai LifeSciences Holdings, Inc., and it allows purchasers of Maravai securities from August 7, 2024, to February 24, 2025, to seek lead plaintiff status by May 5, 2025 [1][5]. - Allegations include that Maravai lacked adequate internal controls over financial reporting, inaccurately recognized revenue during fiscal 2024, and overstated goodwill [3][4]. - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release due to issues related to revenue recognition and a potential non-cash impairment charge, leading to a nearly 22% drop in stock price [4][3]. Group 2: Company Background - Maravai LifeSciences is a provider of biologics that support clinical research [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud cases, having recovered $6.6 billion for investors in such cases [6].